<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03869424</url>
  </required_header>
  <id_info>
    <org_study_id>2019-05k</org_study_id>
    <nct_id>NCT03869424</nct_id>
  </id_info>
  <brief_title>Influence of Expectations on Rumination</brief_title>
  <official_title>Influence of Expectations on Rumination: An Experimental Investigation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Philipps University Marburg Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Philipps University Marburg Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study tries to identify whether positive expectations, induced with an active placebo
      nasal-spray, have effects on rumination.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Healthy volunteers are informed that a new application method for an antidepressant,
      specialised on protecting from rumination, would be tested. They will randomly be assigned to
      the treatment group (taking the antidepressant which is in fact an active placebo) or the no
      treatment control group (not taking a placebo). Then sad mood is induced by mood-suggestive
      music and negative autobiographic recall. Then participants in the experimental group take
      the &quot;medication&quot;. Afterwards both groups are asked to focus on emotion-focused,
      symptom-focused and self-focused thoughts to induce rumination (e.g. &quot;Think about what your
      feelings might mean.&quot;). Sadness will be assessed before and after the negative recall task
      and also after the rumination induction. State Rumination will be assessed before the recall
      task and after the rumination induction.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 27, 2019</start_date>
  <completion_date type="Actual">August 14, 2019</completion_date>
  <primary_completion_date type="Actual">July 31, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in State Rumination (Fragebogen zur Erfassung aktueller Ruminationsneigung)</measure>
    <time_frame>At baseline and after the rumination induction. Each assessment is taking 5 Minutes, in total 10 minutes.</time_frame>
    <description>German questionnaire of 10 Items, e.g.: &quot;I get lost in ruminative thoughts.&quot;, &quot;I am present in this situation.&quot;, &quot;My thoughts are focused on the past.&quot;.All Items will be rated on a visual analogue scale from 0 (not at all) to 10 (very much).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Positive and Negative Affect Schedule (PANAS-X)</measure>
    <time_frame>At baseline, after the negative biographical recall and after the rumination induction, each assessment is taking 3 minutes, in total 9 minutes.</time_frame>
    <description>Items of PANAS-X: Sadness Score (&quot;sad&quot;, &quot;blue&quot;, &quot;downhearted&quot;, &quot;alone&quot;, &quot;lonely&quot;) and Items &quot;Surprised&quot;, &quot;concentrating&quot;, &quot;happy&quot;. All Items will be rated on a visual analogue scale from 0 (not at all) to 10 (very much).</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">90</enrollment>
  <condition>Depression</condition>
  <arm_group>
    <arm_group_label>Positive Expectations Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants receive a nasal spray that is in fact a placebo. However, they are told that it protects from rumination. They take the nasal spray once in the laboratory.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>No-treatment control group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Participants do not receive the nasal spray.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Active Placebo labelled as antidepessant</intervention_name>
    <description>Participants receive an active nasal spray that is in fact a placebo.</description>
    <arm_group_label>Positive Expectations Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  healthy volunteers

          -  fluent in German language

        Exclusion Criteria:

          -  mental disorders

          -  allergic to capsaicin

          -  allergic to sesame oil

          -  intake of psychopharmacological drugs in the last four weeks

          -  intake of illegal drugs in the last two weeks

          -  consumption of alcohol in the last twelve hours

          -  students in medicine, pharmacy, or psychology

          -  completed studies in medicine, pharmacy or psychology

          -  current pregnancy or lactation

          -  cardio vascular disease

          -  kidney disease

          -  liver disease
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Winfried Rief, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Philipps-Univeristy of Marburg</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Philipps-Universit√§t Marburg</name>
      <address>
        <city>Marburg</city>
        <state>Deutschland</state>
        <zip>35032</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>March 8, 2019</study_first_submitted>
  <study_first_submitted_qc>March 8, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 11, 2019</study_first_posted>
  <last_update_submitted>August 15, 2019</last_update_submitted>
  <last_update_submitted_qc>August 15, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 16, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

